{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-009664","form_type":"8-K","ticker":"XTNT","cik":"0001453593","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.332090+00:00","generated_at":"2026-05-21T23:23:43.235235+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Xtant Medical Q1 revenue $32.9M (+18% YoY), net income $58K, raises FY2025 guidance to $127-131M","bullets":["Revenue $32.9M, up 18% vs Q1 2024; net income $58K vs net loss $4.4M prior year.","Adjusted EBITDA $3.0M vs loss $1.0M; cash from operations $1.3M vs use of $5.8M.","FY2025 revenue guidance raised to $127-131M (8-12% growth) from prior $126-130M.","Launched Trivium next-generation DBM allograft; elevated Mark Schallenberger to COO.","Terminated investor rights agreement with OrbiMed; completed secondary share sale led by Nantahala."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-009664","json":"https://secwatch.observer/filing/0001641172-25-009664.json","markdown":"https://secwatch.observer/filing/0001641172-25-009664.md","text":"https://secwatch.observer/filing/0001641172-25-009664.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453593/000164117225009664/0001641172-25-009664-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453593/000164117225009664/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T23:23:43.235235+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}